The latest development is backed by positive results from the DAPA-HF Phase III trial. Credit: Raman Oza from Pixabay.

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Forxiga (dapagliflozin) for treating patients with chronic heart failure (HF) who are receiving standard of care in the country.

Forxiga is an oral, once-daily sodium-glucose co-transporter 2 (SGLT2) inhibitor.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A life-threatening chronic disease, HF prevents the heart from pumping sufficient levels of blood around the body.

The latest development supports positive results from the DAPA-HF Phase III trial conducted on 4,744 patients with HF with reduced ejection fraction (HFrEF).

The international, multi-centre, parallel-group, randomised, double-blinded trial analysed the effect of Forxiga 10mg versus placebo, given once daily along with the standard of care.

Data from the trial showed that Forxiga reduced the risk of cardiovascular (CV) death or worsening of HF events as compared to placebo by 26%.

Forxiga is the first SGLT2 inhibitor to demonstrate a statistically significant reduction in the risk of the composite of CV death or worsening of HF events, including hospitalisation, AstraZeneca noted.

AstraZeneca BioPharmaceuticals R&D executive vice-president Mene Pangalos said: “Forxiga’s efficacy in reducing the risk of cardiovascular death or worsening of heart failure events could result in life-saving benefits for many heart failure patients in Japan.

“Today’s approval will shift the way we manage the disease by providing a treatment option that is urgently needed to improve outcomes and symptoms for these patients.”

At present, Forxiga holds approval in the US, Europe, and many other countries for treating HFrEF patients.

In October, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended Forxiga for an indication extension of its marketing authorisation in the EU.